ロード中...
Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C
The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2% of the world’s population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-α, is expensiv...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2714653/ https://ncbi.nlm.nih.gov/pubmed/20161209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fvl.09.7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|